Aprogen Biologics to issue Convertible Bonds
에이프로젠바이오로직스
003060
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2457
Risk-adjusted indicator based on 2457 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Put Option: Exercisable from November 29, 2027
- • Put Option Rate (1st): 103.0760% on November 29, 2027
- • Put Option Rate (Final): 110.4054% on February 28, 2031
AI Analysis Summary
Aprogen Biologics Inc. has decided to issue convertible bonds. While specific details on the total amount, conversion price, and number of shares to be issued are not provided in this disclosure, the report outlines the terms for bondholders' put options. Bondholders can request early redemption starting November 29, 2027, with redemption rates ranging from 103.0760% to 110.4054% by February 28, 2031. The lack of key issuance details makes a full assessment difficult, but convertible bond issuance typically implies potential future dilution for existing shareholders, hence a negative financial impact.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.